PureTech Health Publishes Data From Phase 2b ELEVATE IPF Study Of Deupirfenidone To Treat Idiopathic Pulmonary Fibrosis

PureTech Health plc has published results from the Phase 2b ELEVATE IPF trial of deupirfenidone for treating idiopathic pulmonary fibrosis (IPF) in The American Journal of Respiratory and Critical Care Medicine. These results will inform the design of the upcoming Phase 3 SURPASS-IPF trial, which will compare deupirfenidone 825 mg TID to pirfenidone 801 mg TID in a head-to-head study. PureTech's Founded Entity, Celea Therapeutics, is seeking financing to initiate the Phase 3 trial in the first half of 2026.